rs5030655

minus

Geno	Mag	Summary
(-;-)	3	CYP2D6*6 poor metabolizer phenotype
(-;T)	2.1	possible CYP2D6 poor metabolizer phenotype
(T;T)	0	normal

Reference

GRCh38 38.1/142

Chromosome

22

Position

42129084

Gene	CYP2D6, LOC102723722, LOC107987465, LOC107987481

is a	snp
is	mentioned by
dbSNP	rs5030655
dbSNP (classic)	rs5030655
ClinGen	rs5030655
ebi	rs5030655
HLI	rs5030655
Exac	rs5030655
Gnomad	rs5030655
Varsome	rs5030655
LitVar	rs5030655
Map	rs5030655
PheGenI	rs5030655
Biobank	rs5030655
1000 genomes	rs5030655
hgdp	rs5030655
ensembl	rs5030655
geneview	rs5030655
scholar	rs5030655
google	rs5030655
pharmgkb	rs5030655
gwascentral	rs5030655
openSNP	rs5030655
23andMe	rs5030655
SNPshot	rs5030655
SNPdbe	rs5030655
MSV3d	rs5030655
GWAS Ctlg	rs5030655

GMAF

0.0101

Max Magnitude

3

The (-) form of this SNP, representing a deletion of one nucleotide, causes a frameshift such that the resulting CYP2D6 protein is nonfunctional. The associated allele is also known as CYP2D6*6, and there are several subtypes but they are all nonfunctional.

If two copies of this (or similar) changes are inherited, CYP2D6 poor metabolism ('PM') is observed.

CYP2D6 poor metabolism may affect the efficacy or degree of side effects of drugs metabolized by CYP2D6, such as dextromorphan, sparteine, nortriptyline, venlafaxine and codeine.

[PMID 20174590 ] Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

ClinVar
Risk	Rs5030655(-;-)
Alt	Rs5030655(-;-)
Reference	Rs5030655(T;T)
Significance	Drug-response
Disease	Debrisoquine
Variation	info
Gene	CYP2D6
CLNDBN	Debrisoquine, poor metabolism of
Reversed	1
HGVS	NC_000022.10:g.42525086delA
CLNSRC	OMIM Allelic Variant
CLNACC	RCV000018387.28,